Flagship Pioneering’s Syros Pharmaceuticals, Inc. Common Stock SYRS Stock Holding History

Flagship Pioneering’s Portfolio SYRS Stock Details SYRS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q4	–	Sell	-1,293,849	Closed	-$2.78M	–	6
2024 Q3	$2.78M	Hold	1,293,849	–	–	0.47%	6
2024 Q2	$6.68M	Hold	1,293,849	–	–	0.79%	6
2024 Q1	$6.92M	Buy	1,293,849 +1	+0%	+$7	0.45%	7
2023 Q4	$10.1M	Buy	1,293,848 +300,000	+30%	+$1.03M	0.76%	7
2023 Q3	$3.93M	Hold	993,848	–	–	0.29%	9
2023 Q2	$3.13M	Hold	993,848	–	–	0.14%	10
2023 Q1	$2.65M	Hold	993,848	–	–	0.1%	10
2022 Q4	$3.57M	Hold	993,848	–	–	0.11%	11
2022 Q3	$6.4M	Buy	993,848 +699,999	+238%	+$5.69M	0.27%	10
2022 Q2	$2.82M	Hold	293,849	–	–	0.11%	12
2022 Q1	$3.5M	Hold	293,849	–	–	0.08%	13
2021 Q4	$9.58M	Hold	293,849	–	–	0.15%	13
2021 Q3	$13.1M	Hold	293,849	–	–	0.14%	13
2021 Q2	$16M	Hold	293,849	–	–	0.2%	12
2021 Q1	$22M	Hold	293,849	–	–	0.35%	12
2020 Q4	$31.9M	Hold	293,849	–	–	0.58%	11
2020 Q3	$26M	Hold	293,849	–	–	0.72%	8
2020 Q2	$31.3M	Hold	293,849	–	–	0.91%	8
2020 Q1	$17.4M	Hold	293,849	–	–	0.82%	8
2019 Q4	$20.3M	Hold	293,849	–	–	1.14%	8
2019 Q3	$30.5M	Sell	293,849 -26,595	-8%	-$2.51M	1.67%	9
2019 Q2	$29.7M	Hold	320,444	–	–	1.28%	10
2019 Q1	$29.3M	Hold	320,444	–	–	1.11%	8
2018 Q4	$17.8M	Hold	320,444	–	–	0.87%	7
2018 Q3	$38.2M	Hold	320,444	–	–	2.52%	6
2018 Q2	$32.7M	Hold	320,444	–	–	6.27%	4
2018 Q1	$41.6M	Hold	320,444	–	–	12.06%	3
2017 Q4	$31.2M	Hold	320,444	–	–	7.91%	5
2017 Q3	$47.2M	Sell	320,444 -160,222	-33%	-$30.1M	15.78%	2
2017 Q2	$77.3M	Hold	480,666	–	–	27.27%	2
2017 Q1	$76.6M	Hold	480,666	–	–	20.35%	2
2016 Q4	$58.4M	Hold	480,666	–	–	19.02%	2
2016 Q3	$66.7M	Buy	+480,666	New	+$61M	18.22%	2

Other funds holding SYRS

BCLSI

Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

OFM

Omega Fund Management Boston, Massachusetts $163M AUM 107.06% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

AAA

Affinity Asset Advisors New York $1.94B AUM 374.45% 1-Year Est. Return

Citigroup New York $235B AUM 32.99% 1-Year Est. Return

Qube Research & Technologies (QRT) London, United Kingdom $89.9B AUM 20.22% 1-Year Est. Return

TSS

Two Sigma Securities New York $861M AUM 21.33% 1-Year Est. Return

Flagship Pioneering's SYRS Position: Q4 2024 in Review

Flagship Pioneering sold out of Syros Pharmaceuticals, Inc. Common Stock (SYRS) in Q4 2024, closing a stake of 1,293,849 shares — an estimated $2.78M sold.

Flagship Pioneering first reported a position in SYRS in Q3 2016 and held it in 33 quarters. The position peaked at $77.3M in Q2 2017. 44 funds tracked by Wall St. Rank hold SYRS as of Q4 2024.

Flagship Pioneering reported no remaining Syros Pharmaceuticals, Inc. Common Stock position as of Q4 2024 after selling out during the quarter.
Flagship Pioneering sold 1,293,849 Syros Pharmaceuticals, Inc. Common Stock shares in Q4 2024, an estimated $2.78M.
Flagship Pioneering first reported a position in Syros Pharmaceuticals, Inc. Common Stock in Q3 2016 and held it in 33 quarters.
Flagship Pioneering's Syros Pharmaceuticals, Inc. Common Stock position peaked at $77.3M in Q2 2017.
44 funds tracked by Wall St. Rank held Syros Pharmaceuticals, Inc. Common Stock as of Q4 2024.

Based on Flagship Pioneering's 13F filing for Q4 2024, filed 14 Feb 2025.